Pub Date : 2023-11-08DOI: 10.33590/emjoncol/10308998
John Marshall
{"title":"Interview: John Marshall","authors":"John Marshall","doi":"10.33590/emjoncol/10308998","DOIUrl":"https://doi.org/10.33590/emjoncol/10308998","url":null,"abstract":"","PeriodicalId":90496,"journal":{"name":"European medical journal. Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135390678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-27DOI: 10.33590/emjoncol/10309426
Brigitte Scott
Endometrial cancer is one of the most common gynaecological cancers in high-income countries, and the incidence is rising significantly. There has recently been a crucial increase in understanding of tumour biology in endometrial cancer, as well as a significant improvement in tailoring surgery and radiotherapy, and the introduction of targeted therapies. In the context of these developments, novel initiatives are needed to increase awareness of new treatment modalities, and infrastructure is required to enable optimal management of patients with endometrial cancer. A co-ordinated, collaborative, multidisciplinary team (MDT) approach in endometrial cancer management promotes shared decision-making and enables comprehensive care of patients, from diagnosis through treatment, via a range of medical specialities and support initiatives. For this article, EMJ conducted an in-depth interview in August 2023 with two key opinion leaders, Domenica (Ketta) Lorusso from the Catholic University of Rome, Italy, and Fondazione Policlinico Universitario Gemelli IRCC, Italy; and Jalid Sehouli from Charité – Universitätsmedizin Berlin, Germany, both of whom have a wealth of experience and expertise in the clinical management of endometrial cancer, and have conducted numerous scientific projects in this field. The experts gave valuable insights into topics such as diagnosis and disease staging in patients with endometrial cancer, measuring the value of an endometrial cancer MDT, and quality control and monitoring of MDT meetings. Lorusso and Sehouli also explored ideas on how to optimise multidisciplinary care in patients with endometrial cancer, including covering aspects of patient management beyond treatment, and how to maintain effective communication between the MDT and the patient. Further topics discussed included empowering nurses in the MDT, managing clinical trial opportunities for patients with endometrial cancer, and aligning MDT recommendations with the expectations of the patient. Finally, Lorusso and Sehouli described what the future of the multidisciplinary management of patients with endometrial cancer might look like.
{"title":"The Importance of the Multidisciplinary Team in the Management of Patients with Endometrial Cancer: Interviews with Two Key Opinion Leaders","authors":"Brigitte Scott","doi":"10.33590/emjoncol/10309426","DOIUrl":"https://doi.org/10.33590/emjoncol/10309426","url":null,"abstract":"Endometrial cancer is one of the most common gynaecological cancers in high-income countries, and the incidence is rising significantly. There has recently been a crucial increase in understanding of tumour biology in endometrial cancer, as well as a significant improvement in tailoring surgery and radiotherapy, and the introduction of targeted therapies. In the context of these developments, novel initiatives are needed to increase awareness of new treatment modalities, and infrastructure is required to enable optimal management of patients with endometrial cancer. A co-ordinated, collaborative, multidisciplinary team (MDT) approach in endometrial cancer management promotes shared decision-making and enables comprehensive care of patients, from diagnosis through treatment, via a range of medical specialities and support initiatives. For this article, EMJ conducted an in-depth interview in August 2023 with two key opinion leaders, Domenica (Ketta) Lorusso from the Catholic University of Rome, Italy, and Fondazione Policlinico Universitario Gemelli IRCC, Italy; and Jalid Sehouli from Charité – Universitätsmedizin Berlin, Germany, both of whom have a wealth of experience and expertise in the clinical management of endometrial cancer, and have conducted numerous scientific projects in this field. The experts gave valuable insights into topics such as diagnosis and disease staging in patients with endometrial cancer, measuring the value of an endometrial cancer MDT, and quality control and monitoring of MDT meetings. Lorusso and Sehouli also explored ideas on how to optimise multidisciplinary care in patients with endometrial cancer, including covering aspects of patient management beyond treatment, and how to maintain effective communication between the MDT and the patient. Further topics discussed included empowering nurses in the MDT, managing clinical trial opportunities for patients with endometrial cancer, and aligning MDT recommendations with the expectations of the patient. Finally, Lorusso and Sehouli described what the future of the multidisciplinary management of patients with endometrial cancer might look like.","PeriodicalId":90496,"journal":{"name":"European medical journal. Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136312223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-24DOI: 10.33590/emjoncol/10302519
Brigitte Scott
Endometrial cancer is the most common gynaecological malignancy in developed countries, and often presents at an early stage. Paclitaxel plus carboplatin is the standard first-line chemotherapy for endometrial cancer; however, there is new evidence that the combination of chemotherapy and immunotherapy has synergistic effects in the treatment of this disease. For this article, EMJ conducted an interview in August 2023 with two key opinion leaders: Jubilee Brown and Wendel Naumann from Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA, both of whom have a wealth of experience and expertise in the management of endometrial cancer. The experts gave valuable insights into recent developments in endometrial cancer research as presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers 2023, held on 25th–28th March 2023 in Tampa, Florida, USA, and online. Topics discussed included the unprecedented progression-free survival (PFS) data from two Phase III randomised controlled trials evaluating first-line immunotherapy in combination with chemotherapy in patients with advanced or recurrent endometrial cancer, RUBY with dostarlimab, and NRG GY018 with pembrolizumab, which created a buzz at SGO 2023. Clinically meaningful benefit of dostarlimab or pembrolizumab in combination with chemotherapy versus standard-of-care chemotherapy was seen regardless of mismatch repair status in RUBY and NRG-GY018, respectively. Brown and Naumann considered the implications of these results on first-line treatment and recurrent settings, and outlined the management of immune-related adverse events related to immunotherapy-based treatment regimens. The experts also explored key earlier stage studies presented at SGO, and the potential for personalised medicine in endometrial cancer. Finally, Brown and Naumann described what the future of the management of patients with endometrial cancer might look like, which clinical trials are needed, and which advancements in research they would like to see.
{"title":"Recent Developments in Endometrial Cancer Research Presented at the Society of Gynecologic Oncology (SGO) Annual Meeting 2023: Interviews with Two Key Opinion Leaders","authors":"Brigitte Scott","doi":"10.33590/emjoncol/10302519","DOIUrl":"https://doi.org/10.33590/emjoncol/10302519","url":null,"abstract":"Endometrial cancer is the most common gynaecological malignancy in developed countries, and often presents at an early stage. Paclitaxel plus carboplatin is the standard first-line chemotherapy for endometrial cancer; however, there is new evidence that the combination of chemotherapy and immunotherapy has synergistic effects in the treatment of this disease. For this article, EMJ conducted an interview in August 2023 with two key opinion leaders: Jubilee Brown and Wendel Naumann from Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA, both of whom have a wealth of experience and expertise in the management of endometrial cancer. The experts gave valuable insights into recent developments in endometrial cancer research as presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers 2023, held on 25th–28th March 2023 in Tampa, Florida, USA, and online. Topics discussed included the unprecedented progression-free survival (PFS) data from two Phase III randomised controlled trials evaluating first-line immunotherapy in combination with chemotherapy in patients with advanced or recurrent endometrial cancer, RUBY with dostarlimab, and NRG GY018 with pembrolizumab, which created a buzz at SGO 2023. Clinically meaningful benefit of dostarlimab or pembrolizumab in combination with chemotherapy versus standard-of-care chemotherapy was seen regardless of mismatch repair status in RUBY and NRG-GY018, respectively. Brown and Naumann considered the implications of these results on first-line treatment and recurrent settings, and outlined the management of immune-related adverse events related to immunotherapy-based treatment regimens. The experts also explored key earlier stage studies presented at SGO, and the potential for personalised medicine in endometrial cancer. Finally, Brown and Naumann described what the future of the management of patients with endometrial cancer might look like, which clinical trials are needed, and which advancements in research they would like to see.","PeriodicalId":90496,"journal":{"name":"European medical journal. Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135273434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-02DOI: 10.33590/emjoncol/10307863.
Hannah Moir
As the medical community continues to explore and harness the potential of biosimilars, it is imperative to accumulate robust real-world evidence (RWE) to guide informed decision-making, and enhance patient outcomes in cancer treatment. This article reviews the current understanding and utilisation of biosimilars in the treatment of breast and lung cancers by reviewing existing RWE. A literature search of PubMed, MEDLINE, and Scopus was performed to analyse observational studies pertaining to the adoption of biosimilars in people living with breast or lung cancer, with publications considered since 2019. The review summarises the current RWE relating to biosimilar use for its approved indications across breast and lung cancer. Despite the scarcity of evidence addressing the cost-effectiveness of biosimilars in breast and lung cancer treatment, biosimilars may offer a dual benefit by enhancing patient outcomes, while ensuring cost-effectiveness, thereby increasing access to oncology therapies globally. The increased access to biosimilars within community oncology practices, hospitals, and national healthcare systems, promises substantial cost savings. This review highlights the evolving landscape of biosimilar utilisation in oncology, revealing their potential as a more affordable and inclusive approach to cancer care, while also indicating areas for further research.
{"title":"Real-World Evidence of Biosimilar Utilisation and Pharmacoeconomics in People Living with Breast or Lung Cancer","authors":"Hannah Moir","doi":"10.33590/emjoncol/10307863.","DOIUrl":"https://doi.org/10.33590/emjoncol/10307863.","url":null,"abstract":"As the medical community continues to explore and harness the potential of biosimilars, it is imperative to accumulate robust real-world evidence (RWE) to guide informed decision-making, and enhance patient outcomes in cancer treatment. This article reviews the current understanding and utilisation of biosimilars in the treatment of breast and lung cancers by reviewing existing RWE. A literature search of PubMed, MEDLINE, and Scopus was performed to analyse observational studies pertaining to the adoption of biosimilars in people living with breast or lung cancer, with publications considered since 2019. The review summarises the current RWE relating to biosimilar use for its approved indications across breast and lung cancer. Despite the scarcity of evidence addressing the cost-effectiveness of biosimilars in breast and lung cancer treatment, biosimilars may offer a dual benefit by enhancing patient outcomes, while ensuring cost-effectiveness, thereby increasing access to oncology therapies globally. The increased access to biosimilars within community oncology practices, hospitals, and national healthcare systems, promises substantial cost savings. This review highlights the evolving landscape of biosimilar utilisation in oncology, revealing their potential as a more affordable and inclusive approach to cancer care, while also indicating areas for further research.","PeriodicalId":90496,"journal":{"name":"European medical journal. Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135900636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Many cancer patients and survivors, between 15 to 90%, report some form of insomnia or sleep quality impairment during and post-treatment, such as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, and waking up too early. Insomnia and sleep quality impairment are among the most prevalent and distressing problems reported by cancer patients and survivors, and can be severe enough to increase cancer mortality. Despite the ubiquity of insomnia and sleep quality impairment, they are under-diagnosed and under-treated in cancer patients and survivors. When sleep problems are present, providers and patients are often hesitant to prescribe or take pharmaceuticals for sleep problems due to poly pharmacy concerns, and cognitive behavioral therapy for insomnia can be very difficult and impractical for patients to adhere to throughout the cancer experience. Research suggests yoga is a well-tolerated exercise intervention with promising evidence for its efficacy in improving insomnia and sleep quality impairment among survivors. This article provides a systematic review of existing clinical research on the effectiveness of yoga for treating insomnia and sleep quality impairment among cancer patients and survivors.
{"title":"Yoga as Treatment for Insomnia Among Cancer Patients and Survivors: A Systematic Review.","authors":"Karen M Mustian","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Many cancer patients and survivors, between 15 to 90%, report some form of insomnia or sleep quality impairment during and post-treatment, such as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, and waking up too early. Insomnia and sleep quality impairment are among the most prevalent and distressing problems reported by cancer patients and survivors, and can be severe enough to increase cancer mortality. Despite the ubiquity of insomnia and sleep quality impairment, they are under-diagnosed and under-treated in cancer patients and survivors. When sleep problems are present, providers and patients are often hesitant to prescribe or take pharmaceuticals for sleep problems due to poly pharmacy concerns, and cognitive behavioral therapy for insomnia can be very difficult and impractical for patients to adhere to throughout the cancer experience. Research suggests yoga is a well-tolerated exercise intervention with promising evidence for its efficacy in improving insomnia and sleep quality impairment among survivors. This article provides a systematic review of existing clinical research on the effectiveness of yoga for treating insomnia and sleep quality impairment among cancer patients and survivors.</p>","PeriodicalId":90496,"journal":{"name":"European medical journal. Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204627/pdf/nihms544176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32769356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-11-01DOI: 10.33590/emjoncol/10311931
K. Mustian
Many cancer patients and survivors, between 15 to 90%, report some form of insomnia or sleep quality impairment during and post-treatment, such as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, and waking up too early. Insomnia and sleep quality impairment are among the most prevalent and distressing problems reported by cancer patients and survivors, and can be severe enough to increase cancer mortality. Despite the ubiquity of insomnia and sleep quality impairment, they are under-diagnosed and under-treated in cancer patients and survivors. When sleep problems are present, providers and patients are often hesitant to prescribe or take pharmaceuticals for sleep problems due to poly pharmacy concerns, and cognitive behavioral therapy for insomnia can be very difficult and impractical for patients to adhere to throughout the cancer experience. Research suggests yoga is a well-tolerated exercise intervention with promising evidence for its efficacy in improving insomnia and sleep quality impairment among survivors. This article provides a systematic review of existing clinical research on the effectiveness of yoga for treating insomnia and sleep quality impairment among cancer patients and survivors.
{"title":"Yoga as Treatment for Insomnia Among Cancer Patients and Survivors: A Systematic Review.","authors":"K. Mustian","doi":"10.33590/emjoncol/10311931","DOIUrl":"https://doi.org/10.33590/emjoncol/10311931","url":null,"abstract":"Many cancer patients and survivors, between 15 to 90%, report some form of insomnia or sleep quality impairment during and post-treatment, such as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, and waking up too early. Insomnia and sleep quality impairment are among the most prevalent and distressing problems reported by cancer patients and survivors, and can be severe enough to increase cancer mortality. Despite the ubiquity of insomnia and sleep quality impairment, they are under-diagnosed and under-treated in cancer patients and survivors. When sleep problems are present, providers and patients are often hesitant to prescribe or take pharmaceuticals for sleep problems due to poly pharmacy concerns, and cognitive behavioral therapy for insomnia can be very difficult and impractical for patients to adhere to throughout the cancer experience. Research suggests yoga is a well-tolerated exercise intervention with promising evidence for its efficacy in improving insomnia and sleep quality impairment among survivors. This article provides a systematic review of existing clinical research on the effectiveness of yoga for treating insomnia and sleep quality impairment among cancer patients and survivors.","PeriodicalId":90496,"journal":{"name":"European medical journal. Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82711172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：